Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($1.66), $0.15 worse than the analyst estimate of ($1.51). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $6.86 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.